Philip D. Bonomi, MD
Liquid biopsies have emerged as an approach to better identify mutations in patients with lung cancer, allowing the unique benefit of allowing clinicians to follow their progress throughout treatment.
on Advanced Non–Small Cell Lung Cancer, Bonomi stressed the importance of good biopsy practices and communication within the oncology community. In an interview during the meeting, Bonomi discussed some of the known biomarkers in non-small cell lung cancer (NSCLC), the utilization of PD-L1, and other testing modalities.
OncLive: Can you discuss your talk on biomarkers in NSCLC?
Probably the most important thing is that we have to make sure we do testing in patients. It’s true that some of the driver mutations are not so common; however, if you don't look for them, you’re definitely not going to find them. You have to get tissue. We have been talking about liquid biopsies, which have been helpful, too. They can't test for all of the mutations, but they can test for the ones that are targetable with approved therapies. A lot of times, people just do a needle aspirate and don’t get enough cells or tissue to do good assays.
... to read the full story